250 related articles for article (PubMed ID: 34463126)
1. Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?
Moujaess E; Merhy R; Kattan J; Sarkis AS; Tomb R
Immunotherapy; 2021 Oct; 13(15):1293-1304. PubMed ID: 34463126
[TBL] [Abstract][Full Text] [Related]
2. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
Ascierto PA; Schadendorf D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
[TBL] [Abstract][Full Text] [Related]
3. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors to treat cutaneous malignancies.
Barrios DM; Do MH; Phillips GS; Postow MA; Akaike T; Nghiem P; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1239-1253. PubMed ID: 32461079
[TBL] [Abstract][Full Text] [Related]
5. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors.
Hooiveld-Noeken JS; Eggen AC; Rácz E; de Vries EGE; Reyners AKL; Jalving M
Crit Rev Oncol Hematol; 2022 Dec; 180():103855. PubMed ID: 36257534
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Stratigos AJ; Sekulic A; Peris K; Bechter O; Prey S; Kaatz M; Lewis KD; Basset-Seguin N; Chang ALS; Dalle S; Orland AF; Licitra L; Robert C; Ulrich C; Hauschild A; Migden MR; Dummer R; Li S; Yoo SY; Mohan K; Coates E; Jankovic V; Fiaschi N; Okoye E; Bassukas ID; Loquai C; De Giorgi V; Eroglu Z; Gutzmer R; Ulrich J; Puig S; Seebach F; Thurston G; Weinreich DM; Yancopoulos GD; Lowy I; Bowler T; Fury MG
Lancet Oncol; 2021 Jun; 22(6):848-857. PubMed ID: 34000246
[TBL] [Abstract][Full Text] [Related]
7. Investigative Landscape in Advanced Non-Melanoma Skin Cancers.
Reddy P; Yao M; Patel M
Curr Treat Options Oncol; 2021 Jun; 22(7):56. PubMed ID: 34097150
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of basal cell carcinoma.
Herms F; Basset-Seguin N
Expert Opin Emerg Drugs; 2021 Mar; 26(1):17-26. PubMed ID: 33412913
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Véron M; Chevret S; Grob JJ; Beylot-Barry M; Saiag P; Fléchon A; You B; Maubec E; Jouary T; Toulemonde E; Jamme P; Gambotti L; Lamrani-Ghaouti A; Dupuy A; Lebbe C; Seguin NB; Houede N; Leccia MT; Le Du F; de Pontville M; Gaudy-Marquestre C; Guillot B; Simon C; Marabelle A; Mortier L
Eur J Cancer; 2022 Dec; 177():103-111. PubMed ID: 36335780
[TBL] [Abstract][Full Text] [Related]
10. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
11. Lasting response after discontinuation of cemiplimab in a patient with locally advanced basal cell carcinoma.
De Giorgi V; Trane L; Savarese I; Silvestri F; Venturi F; Zuccaro B; Scarfì F
Clin Exp Dermatol; 2021 Dec; 46(8):1612-1614. PubMed ID: 34157152
[No Abstract] [Full Text] [Related]
12. Treatment of locally advanced and metastatic basosquamous carcinoma, navigating among sonic hedgehog pathway inhibitors, immune checkpoint inhibitors, chemotherapy, and radiotherapy: A case series and literature review.
Zelin E; Mazzoletti V; Cavallo F; Nardello C; Corio A; Toffoli L; Tagliaferri L; Conforti C; Di Meo N; Zalaudek I
Australas J Dermatol; 2024 Mar; 65(2):103-113. PubMed ID: 37927116
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for Non-melanoma Skin Cancer.
Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
[TBL] [Abstract][Full Text] [Related]
14. Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.
Grund-Gröschke S; Ortner D; Szenes-Nagy AB; Zaborsky N; Weiss R; Neureiter D; Wipplinger M; Risch A; Hammerl P; Greil R; Sibilia M; Gratz IK; Stoitzner P; Aberger F
Mol Oncol; 2020 Sep; 14(9):1930-1946. PubMed ID: 32615027
[TBL] [Abstract][Full Text] [Related]
15. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
16. Emerging trends in the treatment of advanced basal cell carcinoma.
Migden MR; Chang ALS; Dirix L; Stratigos AJ; Lear JT
Cancer Treat Rev; 2018 Mar; 64():1-10. PubMed ID: 29407368
[TBL] [Abstract][Full Text] [Related]
17. Use of PD-1 Inhibitors in the Treatment of Advanced Basal Cell Carcinoma.
Aboul-Fettouh N; Chen L; Silapunt S; Migden MR
Dermatol Surg; 2021 Nov; 47(11):1511-1512. PubMed ID: 34699444
[No Abstract] [Full Text] [Related]
18. The current clinical approach to difficult-to-treat basal cell carcinomas.
Di Brizzi EV; Argenziano G; Brancaccio G; Scharf C; Ronchi A; Moscarella E
Expert Rev Anticancer Ther; 2023 Jan; 23(1):43-56. PubMed ID: 36579630
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
